Organisational unit: Department
Our main goal is to improve the outcome of treatment for haematological cancer patients.
To do this we will:
Characterise and target haematological cancer stem cells in collaborations with Finsen laboratory and BRIC
Monitor imaging and molecular changes that characterise disease entities, predict out come of treatment and guide tailored treatment.
Design and conduct clinical Phase I-III trials
"
Basic/translational research:
Characterization and targeting of haematological cancer stem cells
For all diseases we will design and conduct Phase I-III international clinical trials ,
Additional, disease specific strategies:
AML
Continue our patient involvement program with further development of home-based treatment with chemotherapy
MDS:
Translational programme on scientifically based epigenetic therapy and immune modulation with the VARI, Stand UP2 Cancer, Epigentics Dream Team and the Nordic MDS group.
Malignant lymphoma:
MRD testing and translational studies on MCL genetics/ epigenetics
Development of PET-response adapted treatment strategies.
CLL
Machine Learning in CLL based on Big Data – Development of individually tailored treatment algorithms
Multiple myeloma:
Translations research will focus on immune paresis, epigenetic/genetic variants and drug response prediction
Allogeneic stem cell transplantation:
Transplant programs for alternative donors, implement a myeloablative regimen with reduced toxcicity . Clinical and translational research and immune reconstitution, infections and Graft versus Host Disease.
Basic granulocyte research
Regulation of processing of azurophil granule proteins.
FACS sorting og hematiopoietic stem and progenitor cells
Xenograft mouse models.
High-through-put screening: molecular changes and chemosensitivity
Epigenetics
MRD monitoring
Immune modulation
Big data management
Phase I-III clinical trials
ID: 420